AstraZeneca’s newest addition to its respiratory pipeline is an inhalable medication that could rival a Merck drug approved for treating chronic obstructive pulmonary disease (COPD). The drug, TQC721, ...

Track the company's earnings performance through key income statement metrics such as revenue, net profit, and operating income. Analyse trends in income growth, expenses, profitability, and earnings ...

Scientific computing increasingly requires both accurate simulations of physical systems as well as optimizing them over many parameters for tasks such as inverse ...

Presenters at SECO reviewed a case showing the association between PDE-5 inhibitor use and transient elevations in intraocular pressure. Tadalafil and sildenafil are associated with a transient ...

When you or your child has atopic dermatitis, your doctor might prescribe a topical medication (the kind you apply to your skin). Topical steroids are widely used. But sometimes these don’t work well ...

President Biden’s Department of Education has shelled out at least $1 billion on various diversity, equity and inclusion (DEI) initiatives since 2021, according to a new report. Researchers unearthed ...

The U.S. Department of Education spent at least $1 billion on grants advancing diversity, equity and inclusion (DEI) in hiring, programming and mental health training in America's schools since 2021, ...

Calculation: A representation of a network of electromagnetic waveguides (left) being used to solve Dirichlet boundary value problems. The coloured diagrams at right represent the normalized ...

BPH symptoms may be treated with medication. BPH drugs don’t cure the condition, but they may slow down the growth of your prostate. Benign prostatic hyperplasia (BPH) is a condition that affects ...

The startup will use the financing to advance a pair of cardiovascular medicines and potentially add new therapies to its portfolio. After years of being overlooked by investors, heart and metabolic ...

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) without an identifiable cause. If not treated after diagnosis, the average life expectancy is 3–5 years.